Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis
Objective Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. Patients with RA are at increased risk of developing cardiovascular diseases. This retrospective cohort study aimed to determine whether acetylsalicyl...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605251315359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206293523070976 |
|---|---|
| author | Chao Gao Qiqi Hou Hongxia Cao Cangtuo Li Xu Peng Quanle Han Shouling Wu Kangbo Li |
| author_facet | Chao Gao Qiqi Hou Hongxia Cao Cangtuo Li Xu Peng Quanle Han Shouling Wu Kangbo Li |
| author_sort | Chao Gao |
| collection | DOAJ |
| description | Objective Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. Patients with RA are at increased risk of developing cardiovascular diseases. This retrospective cohort study aimed to determine whether acetylsalicylic acid (aspirin [ASA]) protects against major ischemic vascular events in patients diagnosed with RA. Methods Patients with RA were recruited from a population of 118, 500 participants who were enrolled into the Kailuan Cohort Study between 2014 and 2016. Information regarding demographic characteristics, anthropometric measures, and medical histories were documented. Patients with RA who underwent ASA therapy were propensity score matched at a ratio of 1:4 with patients with RA who did not receive ASA. The risk of ischemic vascular events (myocardial infarction and ischemic stroke) was examined. The relationship between ASA therapy and major ischemic vascular events was analyzed by Cox proportional hazards regression. Results A total of 939 patients with RA were included (189 who received ASA and 750 who did not). During the 3.3-year follow-up, six and 35 major ischemic vascular events occurred in the ASA and non-ASA groups, respectively, with no significant between-group difference in the cumulative incidence of such events. Cox proportional hazards regression analysis showed that ASA therapy was not associated with major vascular ischemic events and its subtypes. Conclusions ASA did not confer protection against major ischemic vascular events in patients diagnosed with RA. |
| format | Article |
| id | doaj-art-324bb64208b34c0daaab82ad0cd0d67b |
| institution | Kabale University |
| issn | 1473-2300 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj-art-324bb64208b34c0daaab82ad0cd0d67b2025-02-07T11:03:24ZengSAGE PublishingJournal of International Medical Research1473-23002025-02-015310.1177/03000605251315359Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritisChao GaoQiqi HouHongxia CaoCangtuo LiXu PengQuanle HanShouling WuKangbo LiObjective Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. Patients with RA are at increased risk of developing cardiovascular diseases. This retrospective cohort study aimed to determine whether acetylsalicylic acid (aspirin [ASA]) protects against major ischemic vascular events in patients diagnosed with RA. Methods Patients with RA were recruited from a population of 118, 500 participants who were enrolled into the Kailuan Cohort Study between 2014 and 2016. Information regarding demographic characteristics, anthropometric measures, and medical histories were documented. Patients with RA who underwent ASA therapy were propensity score matched at a ratio of 1:4 with patients with RA who did not receive ASA. The risk of ischemic vascular events (myocardial infarction and ischemic stroke) was examined. The relationship between ASA therapy and major ischemic vascular events was analyzed by Cox proportional hazards regression. Results A total of 939 patients with RA were included (189 who received ASA and 750 who did not). During the 3.3-year follow-up, six and 35 major ischemic vascular events occurred in the ASA and non-ASA groups, respectively, with no significant between-group difference in the cumulative incidence of such events. Cox proportional hazards regression analysis showed that ASA therapy was not associated with major vascular ischemic events and its subtypes. Conclusions ASA did not confer protection against major ischemic vascular events in patients diagnosed with RA.https://doi.org/10.1177/03000605251315359 |
| spellingShingle | Chao Gao Qiqi Hou Hongxia Cao Cangtuo Li Xu Peng Quanle Han Shouling Wu Kangbo Li Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis Journal of International Medical Research |
| title | Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis |
| title_full | Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis |
| title_fullStr | Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis |
| title_full_unstemmed | Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis |
| title_short | Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis |
| title_sort | aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis |
| url | https://doi.org/10.1177/03000605251315359 |
| work_keys_str_mv | AT chaogao aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis AT qiqihou aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis AT hongxiacao aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis AT cangtuoli aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis AT xupeng aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis AT quanlehan aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis AT shoulingwu aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis AT kangboli aspirindoesnotconferprotectionagainstmajorischemicvasculareventsinpatientsdiagnosedwithrheumatoidarthritis |